Holen Sie sich die Stockscreener-App
6.11
4.09%
0.24
Schlusskurs vom Vortag:
$5.87
Offen:
$5.94
24-Stunden-Volumen:
30,320
Relative Volume:
0.27
Marktkapitalisierung:
$308.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.50M
KGV:
-7.9351
EPS:
-0.77
Netto-Cashflow:
$-30.10M
1W Leistung:
-1.61%
1M Leistung:
+7.76%
6M Leistung:
+55.08%
1J Leistung:
+92.74%
1-Tages-Spanne:
$5.8726
$6.14
1-Wochen-Bereich:
$5.72
$6.44
52-Wochen-Spanne:
$2.6801
$7.19
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.10 | 297.31M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.19 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.40 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.73 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.94 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.32 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Is Eupraxia Pharmaceuticals Inc. stock oversold or undervaluedWeekly Trade Review & Verified Technical Signals - Newser
Will Eupraxia Pharmaceuticals Inc. (X43) stock outperform global peersJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why - Finviz
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Yahoo Finance
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Net current asset value per share of Eupraxia Pharmaceuticals, Inc. – LS:A3EGRS - TradingView
Is Eupraxia Pharmaceuticals Inc. stock a bargain at current levelsWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Is Eupraxia Pharmaceuticals Inc. (X43) stock testing key supportJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser
How Eupraxia Pharmaceuticals Inc. (X43) stock correlates with oil markets2025 Institutional Moves & Weekly High Potential Alerts - Newser
How forex fluctuations impact Eupraxia Pharmaceuticals Inc. (X43) stockPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Eupraxia Pharmaceuticals Inc. (X43) stock expanding market penetration2025 Key Lessons & Low Risk High Win Rate Picks - Newser
(EPRX) Investment Analysis and Advice (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. (EPRX.TO) stock price, news, quote and history - Yahoo Finance UK
Eupraxia Pharmaceuticals (EPRX) Stock Analysis Report | Financials & Insights - Benzinga
How Eupraxia Pharmaceuticals Inc. (X43) stock behaves under inflation pressureOptions Play & Daily Profit Focused Stock Screening - Newser
(EPRX.WT.A) Stock Market Analysis - news.stocktradersdaily.com
Scotia Capital Inc. Reduces Stake in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
(EPRX.WT.A) On The My Stocks Page - news.stocktradersdaily.com
Will Eupraxia Pharmaceuticals Inc. stock deliver better than expected guidanceChart Signals & Expert Approved Momentum Trade Ideas - BỘ NỘI VỤ
Paul Brennan Bought 60% More Shares In Eupraxia Pharmaceuticals - simplywall.st
Eupraxia Pharmaceuticals Appoints New CFO Amid Leadership Transition - MSN
Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Based Buy/Sell Signal Reports - BỘ NỘI VỤ
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Eupraxia Pharmaceuticals Inc. stock reach Wall Street targetsMarket Sentiment Summary & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
(EPRX) Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Long Term Investment Analysis - news.stocktradersdaily.com
(EPRX) Investment Report (EPRX:CA) - news.stocktradersdaily.com
Why Eupraxia Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Bank of Montreal Can Has $215,000 Holdings in Eupraxia Pharmaceuticals Inc. $EPRX - Defense World
Is Eupraxia Pharmaceuticals Inc. (X43) stock supported by strong fundamentals2025 Market Overview & Real-Time Volume Analysis - newser.com
Eupraxia Pharmaceuticals Inc. stock trend forecastTrade Ideas & Fast Moving Market Watchlists - newser.com
How Eupraxia Pharmaceuticals Inc. (X43) stock compares with top peersMarket Rally & Risk Managed Investment Strategies - newser.com
Is Eupraxia Pharmaceuticals Inc. (X43) stock good for long term investingJuly 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
(EPRX) Long Term Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
Volatility clustering patterns for Eupraxia Pharmaceuticals Inc.July 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):